Mohammad Reza Abbaszadegan
Overview
Explore the profile of Mohammad Reza Abbaszadegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
1903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Asadnia A, Nazari E, Goshayeshi L, Zafari N, Moetamani-Ahmadi M, Goshayeshi L, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686578
Colorectal cancer (CRC) is a common cancer associated with poor outcomes, underscoring a need for the identification of novel prognostic and therapeutic targets to improve outcomes. This study aimed to...
12.
Tafazoli A, Abbaszadegan M, Patrinos G
Front Genet
. 2023 Aug;
14:1261876.
PMID: 37600661
No abstract available.
13.
Ajami N, Soleimani A, Jafarzadeh-Esfehani R, Hasanpour M, Rashid Shomali R, Abbaszadegan M
J Cell Mol Med
. 2023 Aug;
27(17):2457-2466.
PMID: 37525467
To date more than 1000 different variants in the PAH gene have been identified in patients with phenylketonuria (PKU). In Iran, several studies have been performed to investigate the genetics...
14.
Ahmadimanesh M, Etemad L, Morshedi Rad D, Ghahremani M, Mohammadpour A, Esfehani R, et al.
Iran J Basic Med Sci
. 2023 Jul;
26(7):820-829.
PMID: 37396946
Objectives: This study aimed to evaluate the effect of SSRIs on the expression of miRNAs and their protein targets. Materials And Methods: In a 100 day open-label study of citalopram...
15.
Ahmadi M, Morshedzadeh F, Ghaderian S, Mousavi P, Habibipour L, Peymani M, et al.
Clin Transl Oncol
. 2023 Jun;
26(1):52-68.
PMID: 37351806
The MAF bZIP transcription factor G-antisense RNA 1 (MAFG-AS1) is located on chromosome 17. MAFG-AS1 was upregulated in 15 human cancers. MAFG-AS1 not only suppresses 16 miRNAs but also directly...
16.
Navaei Z, Khalili-Tanha G, Zangouei A, Abbaszadegan M, Moghbeli M
Oncol Res
. 2023 Jun;
29(4):235-250.
PMID: 37303943
Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However,...
17.
Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, et al.
Mol Biotechnol
. 2023 Jun;
66(2):179-197.
PMID: 37269466
The CRISPR/Cas system, an innovative gene-editing tool, is emerging as a promising technique for genome modifications. This straightforward technique was created based on the prokaryotic adaptive immune defense mechanism and...
18.
Lotfi M, Ashouri A, Mojarrad M, Mozaffari-Jovin S, Abbaszadegan M
Mol Biotechnol
. 2023 Jun;
66(3):517-530.
PMID: 37266832
Beta-thalassemia is one of the most common monogenic inherited disorders worldwide caused by different mutations in the hemoglobin subunit beta (HBB) gene. Genome-editing based on clustered regularly interspaced short palindromic...
19.
Navaei Z, Taghehchian N, Zangouei A, Abbaszadegan M, Moghbeli M
Iran J Basic Med Sci
. 2023 Apr;
26(5):594-602.
PMID: 37051101
Objectives: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid tumor type that has a poor prognosis due to its high therapeutic resistance. Since ATC accounts for half of thyroid cancer-related...
20.
Eslahi A, Alizadeh F, Avan A, Ferns G, Moghbeli M, Abbaszadegan M, et al.
Gene
. 2023 Mar;
867:147358.
PMID: 36914142
Duchenne muscular dystrophy (DMD) is caused by the dystrophin gene mutations and is one of the most common and lethal human hereditary disorders. A novel therapeutic approach using CRISPR technology...